Visugromab Shows Promise in Boosting Bladder Cancer Immunotherapy Before Surgery
A small trial found more complete tumor responses with visugromab plus nivolumab, but larger randomized studies must confirm the benefit.
Summary
Adding the experimental drug visugromab to nivolumab showed encouraging results in a small bladder cancer trial. Researchers enrolled 31 patients whose cancer had invaded bladder muscle and who could not receive or declined cisplatin chemotherapy. Before surgery or repeat tumor removal, patients received nivolumab with either visugromab or placebo. Among patients assessed using removed tissue, no remaining cancer was found in 33% receiving the combination versus 8% receiving nivolumab alone. Neither group experienced treatment-related delays to surgery. However, treatment assignment was not randomized, the groups were small, and the study did not establish whether the combination improves survival. Visugromab blocks a protein that may help tumors evade immune attack. The findings support further trials, not a change in routine care. This summary is based on the abstract only.
Detailed Summary
Muscle-invasive bladder cancer often requires major surgery, and some patients cannot receive or decline cisplatin chemotherapy. Researchers are testing whether blocking GDF-15, a protein that may help tumors resist immune attack, can strengthen nivolumab, an immunotherapy drug. This early trial offers encouraging signals, but does not establish a new standard of care.
The phase 2a study enrolled 31 patients with newly diagnosed bladder cancer that had invaded muscle but had not spread to lymph nodes or distant organs. Sixteen received nivolumab plus visugromab, an antibody targeting GDF-15; fifteen received nivolumab plus placebo. Treatment involved three cycles before bladder surgery or repeat tumor removal. Assignment was sequential rather than randomized.
Among patients assessed for complete disappearance of cancer in removed tissue, responses occurred in five of fifteen receiving the combination, versus one of thirteen receiving nivolumab alone: 33% versus 8%. Imaging responses were 60% versus 15%. Severe treatment-related side effects occurred in 13% versus 20%, and neither group had treatment-related discontinuations or delays to surgery.
Tumors with more cancer-fighting immune cells before treatment were associated with better responses to the combination. Baseline GDF-15 levels and the measured tumor marker PD-L1 did not predict response in this small study. These observations support larger trials and further biomarker research, not using GDF-15 blood testing to select treatment or assuming the combination prolongs survival.
Important limitations include the small sample, nonrandomized allocation, single blinding, locally assessed tissue responses, and wide confidence intervals. Not every enrolled patient contributed to the tissue response analysis, and the abstract does not explain all exclusions. Long-term survival, recurrence, and quality-of-life outcomes are not reported. Many authors disclosed financial ties to the drug developer, including employment, stock interests, or related patents. This summary is based on the abstract only; the full paper was unavailable for assessment of methods and results.
Key Findings
- Complete pathologic responses occurred in 5/15 combination recipients versus 1/13 controls; the small, nonrandomized comparison cannot establish superiority.
- Imaging response rates were 60% with visugromab plus nivolumab versus 15% with nivolumab plus placebo.
- Grade 3–4 treatment-related adverse events occurred in 13% versus 20%; neither group had treatment-related discontinuations or surgery delays.
- Higher baseline tumor CD8 T-cell densities were associated with combination responses; baseline GDF-15 levels were not.
- The findings support larger randomized trials, not routine adoption or claims of improved survival.
Methodology
GDFATHER-NEO was an exploratory, stratified, placebo-controlled, single-blinded, nonrandomized phase 2a trial involving 31 cisplatin-ineligible or cisplatin-refusing patients with clinical T2–T4aN0M0 bladder cancer. Patients were sequentially allocated to three treatment cycles before radical cystectomy or repeat tumor resection; dual primary endpoints were locally assessed pathologic complete response and radiographic response. The trial is registered as NCT06059547.
Study Limitations
The small, nonrandomized, single-blinded trial had wide confidence intervals, locally assessed pathologic responses, and fewer evaluable patients than enrolled patients. Long-term survival and recurrence outcomes were not reported, and numerous authors disclosed financial relationships with the developer. This summary is based on the abstract only, preventing independent assessment of full methods and results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: